Abstract
Multiple karyotypic abnormalities and chromosomal instability are characteristic features of many cancers that are relatively resistant to chemotherapeutic agents currently used in the clinic. These same features represent potentially targetable “states” that are essentially tumor specific. The assessment of the chromosomal state of a cancer cell population may provide a guide for the selection or development of drugs active against aggressive and intractable cancers.
Keywords: Aneuploidy, Chromosomal instability, Cancer, Anticancer drugs, NCI-60, Karyotic abnormalities, CIN, Chromosomal instability phenotype, Heterogeneity, Cancer progression, Chemotherpeutic agents, Anticancer therapy, Drosophila, Trisomies, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Neoplasia, Tumorigenesis, Microsatellite instability, CENP-E heterozygous, Chromatid cohesion, Centrosomes, Kinetochore, Chromosome missegregating, JAK-STAT signaling pathways, ECM-receptor interaction pathways, Griseofulvin, Cancer spectrum, GI50 data vectors, Anthracyclines, Antifolates, Alkylators, Topoisomerase agents, Gemcitabine, 5-fluorouracil, Mercapto-3H quinazolines
Current Drug Targets
Title: Targeting Karyotypic Complexity and Chromosomal Instability of Cancer Cells
Volume: 11 Issue: 10
Author(s): Anna V. Roschke and Ilan R. Kirsch
Affiliation:
Keywords: Aneuploidy, Chromosomal instability, Cancer, Anticancer drugs, NCI-60, Karyotic abnormalities, CIN, Chromosomal instability phenotype, Heterogeneity, Cancer progression, Chemotherpeutic agents, Anticancer therapy, Drosophila, Trisomies, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Neoplasia, Tumorigenesis, Microsatellite instability, CENP-E heterozygous, Chromatid cohesion, Centrosomes, Kinetochore, Chromosome missegregating, JAK-STAT signaling pathways, ECM-receptor interaction pathways, Griseofulvin, Cancer spectrum, GI50 data vectors, Anthracyclines, Antifolates, Alkylators, Topoisomerase agents, Gemcitabine, 5-fluorouracil, Mercapto-3H quinazolines
Abstract: Multiple karyotypic abnormalities and chromosomal instability are characteristic features of many cancers that are relatively resistant to chemotherapeutic agents currently used in the clinic. These same features represent potentially targetable “states” that are essentially tumor specific. The assessment of the chromosomal state of a cancer cell population may provide a guide for the selection or development of drugs active against aggressive and intractable cancers.
Export Options
About this article
Cite this article as:
V. Roschke Anna and R. Kirsch Ilan, Targeting Karyotypic Complexity and Chromosomal Instability of Cancer Cells, Current Drug Targets 2010; 11 (10) . https://dx.doi.org/10.2174/1389450111007011341
DOI https://dx.doi.org/10.2174/1389450111007011341 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Circular RNAs and Glioma: Small Molecule with Big Actions
Current Molecular Medicine Reduction of Breast Cancer Relapses with Perioperative Non-Steroidal Anti-Inflammatory Drugs: New Findings and a Review
Current Medicinal Chemistry Identification of Prognostic Biomarkers in Papillary Thyroid Cancer and Developing Non-Invasive Diagnostic Models Through Integrated Bioinformatics Analysis
MicroRNA Merlin, a “Magic” Linker Between the Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell Motility, Proliferation, and Survival
Current Protein & Peptide Science Critical microRNAs in Lung Cancer: Recent Advances and Potential Applications
Anti-Cancer Agents in Medicinal Chemistry Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale
Current Pharmaceutical Design Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms
Anti-Cancer Agents in Medicinal Chemistry DNAzyme Delivery Approaches in Biological Settings
Current Medicinal Chemistry Human Endometrial and Ovarian Cancer Cells: Histone Deacetylase Inhibitors Exhibit Antiproliferative Activity, Potently Induce Cell Cycle Arrest, and Stimulate Apoptosis
Current Medicinal Chemistry Is it Possible to Treat Osteosarcoma Using Oligonucleotides Confined into Controlled Release Drug Delivery Systems?
Current Pharmaceutical Biotechnology Current Challenges in Targeting Tumor Desmoplasia to Improve the Efficacy of Immunotherapy
Current Cancer Drug Targets Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets Expression of NRP-1 and NRP-2 in Endometrial Cancer
Current Pharmaceutical Biotechnology Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews Acridine Orange is an Effective Anti-Cancer Drug that Affects Mitochondrial Function in Osteosarcoma Cells
Current Pharmaceutical Design Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design Dose-Intensive Chemotherapy with Stem Cell Support as a Treatment Strategy for Bone and Soft-Tissue Sarcomas
Current Stem Cell Research & Therapy Cancer and Treatment Modalities
Current Cancer Therapy Reviews Nanoparticle Based Delivery of Protease Inhibitors to Cancer Cells
Current Medicinal Chemistry